decay, thus enhancing cell viability. Finally, we applied our method to UPF1 and showed 10 that UPF1-mediated mRNA decay was activated by rapamycin. Thus, our study 11 establishes a systematic and un-biased strategy to identify the biological role of RBPs 12 through the identification and analysis of transcripts directly regulated by RBPs. 
conditions/stimuli under which the TF-mediated gene expression is regulated 27 (transcriptional activation or repression) (Segal et al., 2003) . In contrast to the success in 28 studying TFs, an analytical framework for RBPs that regulate RNA stability remains We present an analytical framework that combines the experimental 3 identification of functional targets of RBPs and the computational identification of stimuli 4 that modulate RBP-mediated gene regulation. In this study, "bona-fide targets" of the 5 RBP of interest are experimentally determined as transcripts that satisfy the following 6 two criteria: (1) a transcript bound to the RBP and (2) a transcript for which the stability 7 is affected in the RBP-depleted cells. By applying this method, we previously identified 8 246 targets of UPF1 (Imamachi et al., 2016) . To develop a computational pipeline that 9 identifies the combination of stimuli and RBP-mediated gene regulation, we constructed 10 an in silico screening scheme by using the publicly available RNA-seq data of human level in response to a certain stimulus, the expression change in the RBP will be inversely 13 correlated with that of the targets. Based on this assumption, in silico screening may be 14 used to identify a stimulus that promotes or inhibits RBP-mediated mRNA decay ( Figure   15 1). Overall, our method specifies the post-transcriptional regulation of particular 16 transcripts governed by the RBP of interest under specific conditions. Our method thus 17 generates testable hypotheses that suggest the biological roles for an RBP and the 18 conditions under which it acts. 19 We applied our methodology to human PUMILIO (PUM) proteins (Miller and In this study, we initially identified 49 mRNAs as bona-fide targets of PUM1.
33
In silico screening of 481 RNA-seq data deposited on Gene Expression Omnibus (GEO) 34 identified DNA damage agents as an inhibitory stimulus for PUM1-mediated mRNA 35 decay. We experimentally tested this computational prediction and identified the 36 5 biological role of PUM1 in the cellular resistance to DNA damage agents. This 1 experimental result verified the method's predictions and provided the previously 2 uncharacterized role of PUM1. Finally, we also applied the method to another RBP, UPF1, 3 and demonstrated that UPF1-mediated mRNA decay is promoted by a rapamycin 4 stimulus, thus highlighting the generality of our method. 
Results

2
Strategy to systematically study the biological function of RBP-mediated mRNA 3 decay. 4 Our methodology comprises two parts: (i) the identification of bona-fide target 5 mRNAs of the RBP and (ii) the identification of stimuli that regulate the RBP-mediated 6 mRNA decay (Figure 1) . Bona-fide targets of the RBP of interest are defined by two (Figure 1) . Through this analysis, we can identify the functional 18 connection between an RBP of interest and its targets.
19
To investigate the biological role of the RBP, we aimed to identify external 20 stimuli that modulate RBP-mediated mRNA decay. Our analysis is based on the following 21 idea: If the expression levels of the RBP and its targets respond to a stimulus in an inverse-22 correlated manner, the stimulus is regarded as a candidate modulator (promoter or 23 inhibitor) of RBP-mediated mRNA decay (Figure 1) . To identify these stimuli, we 24 developed an analytical pipeline for in silico screening of the massive dataset, which 25 contains hundreds of RNA-seq profiles deposited in Gene Expression Omnibus (GEO).
26
In this pipeline, the alteration of the expression levels of the RBP (mRNA) and its targets 27 to stimuli is quantified by calculating the fold-change of the mRNA expression levels in 
34
The human PUM family consists of two members encoded in independent genes 35 (PUM1 and PUM2) that share 83% overall similarity, with the RNA-binding domain 36 7 (PUM-HD) being 97% similar (Spassov and Jurecic, 2002) (Figure 2A) and FLAG-tagged PUM2 with a similar over-expression level in HeLa Tet-off (TO) cells.
4
By setting the cutoff limit for the false discovery rate at 0.05, we determined 3,097 and 5 2,813 mRNAs bound to PUM1 and PUM2, respectively ( Figure 2B , Table S1 ). Both 6 PUM1 and PUM2 shared most of their binding targets (2,671 mRNAs, Figure 2C ). 7 Moreover, the fold enrichment of the PUM1-bound mRNAs was highly correlated with 8 that of the PUM2-bound mRNAs (R 2 = 0.97, Figure 2D ). We confirmed the specific 9 binding of mRNAs on FLAG-PUMs via RIP-qPCR ( Figure S1A, upper panel) . In 10 addition, we confirmed mRNAs bound to endogenous PUMs using specific antibodies there was no effect of PUM KD for a transcript that lacked PUM motif, such as ABCC1 Table   33 S1, Figure S1D ).
34
By merging the results of BRIC-seq with RIP-seq, we identified 48 transcripts 35 that were associated with PUM1 and were significantly stabilized in PUM1 KD cells 36 8 ( Figure 2H , Table S1 ). although the binding ability of PUM2 to mRNAs and RNA decay factors is nearly 7 equivalent to that of PUM1 ( Figure 2D, Figure S2 ). If we consider that both PUM1 and to a non-silenced condition ( Figure S3C ). Thus, the negligible effect of PUM2 on mRNA
12
degradation in HeLa TO cells may be explained by the low expression of PUM2.
14
Identification of DNA damage agents as inhibitors of PUM1-mediated mRNA decay.
15
The initial bioinformatic analysis using PANTHER did not show functional 16 enrichment in the 48 PUM1 targets, which suggests that a novel analytical pipeline is 17 required to investigate the biological role of PUM1-mediated mRNA decay. To this end,
18
we developed an in silico screening scheme to identify a specific stimulus that influences , Table S2 ).
24
To quantify whether the overall trend of PUM1 targets is increased or decreased following 25 a stimulus, we introduced a "variation index". This index is defined by the sum of 26 numbers of increased and decreased PUM1 targets ( Figure 3B , also refer to Methods).
27
Each variation index of PUM1 targets was plotted against the corresponding log2-fold- decay.
34
For promoters of PUM1-mediated mRNA decay, ailanthone (AIL) and a mixture transcripts that we should experimentally analyze in detail.
35
Suppression of PUM1-mediated mRNA decay by DNA damage agents. 36 We verified the results of the in silico screening by measuring the PUM1 protein 1 level and its target mRNA levels in drug-treated cells. We selected three core targets 
). However, the SLC25A12 mRNA levels did not change with CDDP in HCT116 and 10 A549 cells. We also examined the effect of CPT on HeLa TO cells and determined that
11
CPT decreased the PUM1 expression levels and increased only the core target mRNA 12 levels ( Figure S5B ). These results indicated that the DNA damage agents decrease PUM1
13
protein levels and increase PUM1-target transcript levels. Notably, the increases of the control cells (Figure 5D ). In contrast, the overexpression of Δ PUM-HD, which did not 5 restore the PUM-mediated mRNA decay, did not reduce the survival rate ( Figure 5D ). 6 Taken together, our results suggest that the loss of PUM1 in response to DNA damage Generality of in silico screening: application to UPF1 study.
11
To demonstrate the generality of our in silico screening, we applied our approach
12
to up-frameshift protein 1 (UPF1). UPF1 is a well-known core factor of the nonsense- 
).
22
The in silico screening of RNA-seq data suggested that Zaire ebolavirus (EBOV) 23 and Reston ebolavirus (RESTV) suppress UPF1-mediated mRNA decay, whereas 24 rapamycin promotes UPF1-mediated mRNA decay ( Figure 6A) . A previous study 25 demonstrated that rapamycin down-regulated UPF1-regulated mRNAs, which was an inverse-correlated effect on UPF1 and its targets, thus demonstrating that our in silico 31 screening of RNA-seq data is applicable to the other RBP study. supported by a Grant-in-Aid for JSPS Fellows (17J11266). 
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9
All plasmids were prepared using the PureYield Plasmid Midiprep System 10 (Promega, Madison, WI) for transfection to cells. added to the cells, followed by a 6-hour incubation at 37 °C with 5% CO2. The OptiMEM 20 medium was subsequently replaced by culturing medium (DMEM with FBS).
21
Transfected cells were used for further studies at 24-hours post-transfection.
22
All siRNAs were synthesized by Hokkaido System Science (Hokkaido, Japan). Table S4 . 28 
29
Sample preparation for RNA-immunoprecipitation sequencing (RIP-seq) 30 Plasmid cloned FLAG-tagged PUM1 or PUM2 was transfected into HeLa TO were washed with 1 mL PLB two times.
9
The supernatants were mixed with antibody-bead conjugates and rotated for 2- Thirty-six base pair single-end read RNA-seq tags were generated using an Illumina
22
HiSeq 2500, according to the standard protocol. The fluorescent images were processed 23 to nucleotide sequences using the analysis Pipeline supplied by Illumina.
25
Motif identification
26
To validate the putative binding motif for PUM in the 3'UTRs of the transcripts bound to 27 PUM, we performed de novo motif discovery on the sequences using multiple EM for 28 motif elicitation (MEME). To reduce the calculation time, the top 100 transcripts of the 29 RIP-seq fold change were selected for the MEME analysis. Here, 3'UTR was defined in 30 the RefSeq annotation data.
32
Bromo-uridine (BrU) immunoprecipitation chase-deep sequencing (BRIC-seq) 33 BRIC was performed as previously described (Yamada et al., 2018) . In brief, cells were 34 incubated at 37 °C in the presence of 150 μM bromo-uridine (BrU) (Wako Chemical,
35
Tokyo, Japan) for 24-hours in a humidified incubator with 5% CO2. Cells were harvested 36 at the indicated time points after replacing BrU-containing medium with BrU-free 1 medium. Total RNA was isolated using RNAiso Plus (Takara), followed by the isolation 2 of BrU-labeled RNA using anti-BrdU mouse antibody (clone 2B1, MBL, Nagoya, Japan).
3
The isolated RNA was used for high-throughput sequencing as described in the "Sample 4 preparation for RNA-immunoprecipitation sequencing (RIP-seq)" section.
6
Sample preparation of IP-Mass spectrometry analysis 7 The preparation of cell lysate for IP-mass is exactly the same procedure for RIP-seq (refer Fisher Scientific) were washed three times in PLB and were resuspended in 1 mL of PLB.
12
Fifteen μL of anti-FLAG M2 mouse monoclonal antibody were added to the beads. After trapping time was 100 milliseconds with the auto gain control on.
23
Reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR) 24 The isolated RNA was reverse transcribed into cDNA using the PrimeScript RT Master
25
Mix (Takara). cDNA was amplified using the primer sets listed in Table S4 with SYBR
26
Premix Ex Taq II (Takara) in accordance with the manufacturer's instructions. RT-qPCR 27 analysis was performed using a Thermal Cycler Dice Real Time System (Takara). The
28
GAPDH and PGK1 mRNAs were used for transcript normalization. For the UPF1 study,
29
SDHA mRNA was used for normalization. The relative value of the transcript was 30 calculated using the comparative CT method (∆∆CT). We analyzed three biological 31 replicates with two technological replicates for each experiment.
33
Western blotting
34
Total protein extracts were prepared in RIPA buffer and separated on a 10% sodium Preprocessing, mapping, and quantification of sequencing data
35
Low quality reads were discarded using the FASTX-toolkit and reads that contained less were considered expressed for subsequent analysis. Identification of transcripts bound to PUM
11
We set the threshold of the fold discovery rate, calculated using Cufflinks (version 2.1.1),
12
to less than 0.05 for the transcripts of which the RPKM is greater than 1.0 in the
13
corresponding RIP-PUM sample.
15
Calculation of RNA half-life and estimation of significant fold-change with PUM KD
16
The RNA-half life was calculated as previously described. Briefly, the relative expression 17 data of each transcript at each time point were normalized using the 97.5% percentile. To the peptides were set to 95% minimum and the thresholds of the proteins were set to 99% 3 minimum with 3 peptides minimum.
4
To determine the PUM-associated proteins, we set the threshold to a five-fold enrichment 5 in PUM immunoprecipitants compared to the control. RPKM in RNA-seq.
13
Motif searches
14
The 3'UTRs of the sequences were retrieved from GenBank (RefSeq, hg19). The PUM 15 motif was searched using MEME (http://meme-suite.org/). To assign statistical 16 significance to the reported PUM motif, we applied the E-value, which is automatically 17 calculated in the MEME program.
19
In silico screening of RNA-seq
20
To generate the complete datasets for screening, GEO was queried in terms of 'human',
21
'inhibitor', or 'stress'. After the collection of the SRA files, mapping and quantification
22
of the RNA-seq data were performed as described in the "Preprocessing, mapping, and 23 quantification of sequencing data" section. For each RNA-seq data, the log2-fold-changes 24 of the PUM1 and PUM1 targets were calculated. To estimate the correlation between the 25 PUM1 and PUM1 targets, the "Variation Index of targets" was calculated as follows,
26
Variation Index = "the number of increased PUM1 targets (log2-fold-change > 1)" -"the 27 number of decreased PUM1 targets (log2-fold-change < -1)". A scatter plot was used to 28 investigate the potential relationship between the log2-fold-change of PUM1 and the
29
Variation index. In the scatter plot, RNA-seq that suggests a stimulus inhibits PUM1-30 mediated mRNA decay will be plotted in the second quadrant, whereas RNA-seq that 31 suggests a stimulus promotes PUM1-mediated mRNA decay will be plotted in the fourth 32 quadrant. All codes are freely available at the github repository
33
(https://github.com/Imamachi-n/AutoNGS).
34
For in silico screening with the UPF1 and UPF1 targets, we focused on 51 avoid this failure, we also considered the increase of mRNA amounts by UPF1 KD. The accession numbers for the mass spectrometry data reported in this paper are in cell survival to DNA damage agents. Galgano, A., Forrer, M., Jaskiewicz, L., Kanitz, A., Zavolan, M., and Gerber, A.P. 
